Investment House LLC acquired a new stake in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, according to its most recent filing with the SEC. The institutional investor acquired 4,961 shares of the biopharmaceutical company’s stock, valued at approximately $913,000.

Several other hedge funds have also recently made changes to their positions in SHPG. UBS Group AG boosted its position in Shire PLC by 1,825.2% in the first quarter. UBS Group AG now owns 1,227,631 shares of the biopharmaceutical company’s stock valued at $211,030,000 after buying an additional 1,163,865 shares during the last quarter. Rockefeller Financial Services Inc. boosted its position in Shire PLC by 142.7% in the second quarter. Rockefeller Financial Services Inc. now owns 615,314 shares of the biopharmaceutical company’s stock valued at $113,266,000 after buying an additional 361,743 shares during the last quarter. Lazard Asset Management LLC boosted its position in Shire PLC by 8.3% in the first quarter. Lazard Asset Management LLC now owns 604,947 shares of the biopharmaceutical company’s stock valued at $103,989,000 after buying an additional 46,519 shares during the last quarter. BlackRock Fund Advisors boosted its position in Shire PLC by 10.0% in the first quarter. BlackRock Fund Advisors now owns 591,458 shares of the biopharmaceutical company’s stock valued at $101,672,000 after buying an additional 53,889 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Shire PLC by 12.6% in the first quarter. Renaissance Technologies LLC now owns 313,212 shares of the biopharmaceutical company’s stock valued at $53,841,000 after buying an additional 35,100 shares during the last quarter. Hedge funds and other institutional investors own 24.26% of the company’s stock.

Shire PLC (NASDAQ:SHPG) traded down 1.24% on Wednesday, hitting $204.00. 1,659,371 shares of the company traded hands. The stock’s 50-day moving average is $196.07 and its 200 day moving average is $183.99. Shire PLC has a 12 month low of $147.60 and a 12 month high of $231.32. The firm has a market capitalization of $60.76 billion, a P/E ratio of 42.39 and a beta of 1.11.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The firm earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. During the same quarter in the prior year, the firm posted $2.63 earnings per share. Shire PLC’s quarterly revenue was up 55.9% on a year-over-year basis. Equities analysts forecast that Shire PLC will post $12.93 EPS for the current fiscal year.

The company also recently disclosed a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be issued a $0.139 dividend. The ex-dividend date is Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.

SHPG has been the subject of several research analyst reports. Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a research note on Tuesday, August 30th. Zacks Investment Research raised shares of Shire PLC from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a research note on Tuesday, July 5th. Citigroup Inc. reaffirmed a “buy” rating on shares of Shire PLC in a research note on Monday. Leerink Swann reaffirmed a “buy” rating and set a $213.00 target price (down from $225.00) on shares of Shire PLC in a research note on Thursday, June 16th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 28th. Four equities research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $230.67.

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

5 Day Chart for NASDAQ:SHPG

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.